Related Experiment Video
Updated: Feb 20, 2026
08:45
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
14.2K
ASGR1 - a new target for lowering non-HDL cholesterol
Mohamed Hassan1, Kerolos Wagdy1
1Division of Cardiology, Aswan Heart Center, Aswan, Egypt.
Global Cardiology Science & Practice
|October 19, 2017
Summary
A rare ASGR1 gene mutation lowers non-HDL cholesterol and coronary heart disease risk. This genetic finding suggests novel therapies targeting the sialylation pathway for heart disease prevention.
Area of Science:
- Genetics
- Cardiology
- Biochemistry
Background:
- Non-HDL cholesterol (non-HDL-C) is a key cardiovascular risk marker.
- ASGR1 gene mutations are linked to plasma non-HDL-C levels and coronary heart disease (CHD).
Purpose of the Study:
- To investigate the association between a specific ASGR1 gene mutation (del12 deletion) and cardiovascular outcomes.
- To explore the cardioprotective mechanisms beyond cholesterol reduction.
Main Methods:
- Genetic analysis of the Icelandic population.
- Correlation of ASGR1 (asialoglycoprotein receptor 1) genotype with non-HDL-C levels and CHD risk.
Main Results:
- Heterozygous carriers of the ASGR1 del12 deletion showed significantly lower non-HDL-C levels (-13.6 mg/dl).
- These carriers had a 34% reduced risk of coronary heart disease.
- The cardioprotective effect exceeded predictions based solely on cholesterol reduction.
Conclusions:
- The ASGR1 del12 mutation confers substantial protection against CHD, suggesting mechanisms beyond lipid lowering.
- The sialylation pathway is implicated, offering a potential new target for heart disease therapies.
- Targeting ASGR1 may represent a novel therapeutic strategy for cardiovascular disease prevention.
Related Concept Videos
01:26Atherosclerosis III: Management
465
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
465
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
01:29Pharmacogenomics: Identification of New Drug Targets
27
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
27
01:29Cholesterol: Significance and Regulation
1.6K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.6K
01:26Coronary Artery Disease IV: Preventive Measures
741
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
741
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.8K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.8K